D
Dimitris D. Tsiftsis
Researcher at University of Crete
Publications - 60
Citations - 1595
Dimitris D. Tsiftsis is an academic researcher from University of Crete. The author has contributed to research in topics: Breast cancer & Sentinel lymph node. The author has an hindex of 23, co-authored 59 publications receiving 1493 citations.
Papers
More filters
Journal ArticleDOI
The clinical significance of acquired jejunoileal diverticula
TL;DR: Jejunoileal diverticula should not always be dismissed as asymptomatic findings, as they may be the cause of vague, chronic symptomatology and acute complications, including intestinal obstruction, hemorrhage, and perforation.
Journal ArticleDOI
Desmoid tumors: need for an individualized approach
TL;DR: Treatment of desmoid tumor is individualized to reduce local tumor control failure with concurrently acceptable morbidity and preservation of quality of life, and systemic treatment may be indicated in patients that have anatomic barriers to effective surgery or radiotherapy.
Journal ArticleDOI
Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.
Eelco de Bree,Panayiotis A. Theodoropoulos,Hilde Rosing,John Michalakis,John Romanos,Jos H. Beijnen,Dimitris D. Tsiftsis +6 more
TL;DR: Experimental studies show that at high locoregional concentrations there seems to be such an effect of thermal enhancement of taxane cytotoxicity, and feasibility and efficacy of this treatment have evidently been demonstrated in various clinical studies.
Journal ArticleDOI
How many cases are enough for accreditation in sentinel lymph node biopsy in breast cancer
TL;DR: The number of procedures of the learning curve can not be fixed for all surgeons and only surgeons in specialized breast cancer centers can succeed in meeting current recommendations with 20 to 30 cases.
Journal ArticleDOI
Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study
Eelco de Bree,Hilde Rosing,Dimitris Filis,John Romanos,Maria Melisssourgaki,Markos Daskalakis,Maria Pilatou,Elias Sanidas,Panagiotis Taflampas,Konstantinos Kalbakis,Jos H. Beijnen,Dimitris D. Tsiftsis +11 more
TL;DR: HIPEC with paclitaxel following cytoreductive surgery is feasible, relatively safe, and associated with a highly favorable pharmacokinetic profile, despite its short treatment duration.